| Patient | Ida B. Wells |
|---|---|
| Date of birth | 1957-07-16 |
| Identifiers | MRN HR-ET022-SYN; SSN (made up) 000-22-5903 |
| Document date | 2026-03-03 |
| Author | Cordelia Ashworth-Banks, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four weeks after starting dapagliflozin: potassium, creatinine and blood pressure, the losartan dose, and the plan for the months ahead. [S]
Mrs. Wells returns two weeks after her annual wellness visit and four weeks after starting dapagliflozin. She has had no dizziness, genital itching or sick days. Her home readings average 130/78. Her ankles have not swollen for three weeks and her afternoons are easier, though she still tires on long writing days. Since the kidney education session she has written down her questions about transplant evaluation for her next nephrology visit. She asked for the COVID-19 vaccine today. [S]
| Element | Detail |
|---|---|
| Home blood pressure | Average 130/78 |
| Side effects | None |
| Symptoms | No ankle swelling; less tired |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Less tired; tires on long writing days |
| Cardiovascular | Negative | No ankle swelling |
| Genitourinary | Negative | No burning or genital itching |
| Neurological | Negative | No dizziness |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, one or two tablets up to three times a day as needed for knee aching (no more than 3,000 mg a day), in place of naproxen | One or two tablets up to three times a day as needed | Oral route | 2026-01-05 | active | S |
| Losartan 50 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating | One tablet daily, with sick-day rules | Oral route | 2026-01-20 to 2026-03-03 | completed | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-20 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-20 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery | One tablet daily, with sick-day rules | Oral route | 2026-02-03 | active | S |
| Losartan 100 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating | One tablet daily, with sick-day rules | Oral route | 2026-03-03 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-03 | Body height | 157 | cm | S |
| 2026-03-03 | Body weight | 68.9 | kg | S |
| 2026-03-03 | Body mass index (BMI) [Ratio] | 28 | kg/m2 | S |
| 2026-03-03 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-03-03 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-03-03 | Heart rate | 72 | /min | S |
| 2026-03-03 | Respiratory rate | 16 | /min | S |
| 2026-03-03 | Body temperature | 36.6 | Cel | S |
| 2026-03-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-03 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-03 | Potassium [Moles/volume] in Serum or Plasma | 4.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-03 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | Keep at 22 or above in kidney disease | Normal | S |
| 2026-03-03 | Urea nitrogen [Mass/volume] in Serum or Plasma | 31 | mg/dL | 8-23 mg/dL | High | S |
| 2026-03-03 | Creatinine [Mass/volume] in Serum or Plasma | 1.56 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-03-03 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 36 | mL/min/{1.73_m2} | 60 or higher without other kidney damage markers; 45 to 59 is G3a, 30 to 44 is G3b, 15 to 29 is G4 | Low | S |
Vital signs recorded on 2026-03-03; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 132/80, pulse 72; weight 68.9 kg |
| Cardiovascular | Regular rhythm; no ankle swelling |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Tiredness for some months and ankle swelling by evening, with a raised creatinine (1.42 mg/dL, race-free eGFR 40, confirmed at 38 with cystatin C) and albumin in the urine (240 mg/g) found today; cause and chronicity to be established | resolved | confirmed | R94.4 | S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks. |
| Elevated blood pressure at intake (164/94 mmHg, average of two readings), without a diagnosis of hypertension; home readings for one week to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks. |
| Hypertension, stage 2, confirmed by home readings (average 150/88 mmHg), with chronic kidney disease | active | confirmed | I12.9 | S — Synthetic modern diagnosis; no blood pressure from her life is recorded. |
| Chronic kidney disease G3b A2 (eGFR 38 by creatinine and cystatin C, urine albumin-to-creatinine ratio 240 and 228 mg/g), present at least two years; small, echogenic kidneys without obstruction; most likely hypertensive kidney disease, with APOL1-associated disease possible; 5-year kidney failure risk about 7% | active | confirmed | N18.32 | S — Synthetic modern diagnosis linked to the kidney disease recorded at her death. |
| Anemia of chronic kidney disease, mild (hemoglobin 11.2 g/dL) with adequate iron stores; a likely part of her tiredness | active | confirmed | D63.1 | S — Synthetic laboratory finding. |
| Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL) with a mildly raised PTH (84 pg/mL); calcium and phosphate normal | active | confirmed | E55.9 | S — Synthetic laboratory finding, part of the mineral and bone check in kidney disease. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Standardized office blood pressure (five minutes' rest, validated cuff, average of two readings) | Every visit | Completed today | 132/80 |
| Self-management | Home blood pressure readings | Seven days to confirm; then the week before each visit while medicines change | Completed today | Average 130/78 |
| Laboratory | Potassium, sodium, bicarbonate, urea nitrogen, creatinine and eGFR | Two to four weeks after starting or increasing an ARB or SGLT2 inhibitor; then with each eGFR check (about twice a year at G3b A2) | Completed today | Four weeks after dapagliflozin: sodium 139, potassium 4.8, bicarbonate 23 mmol/L; urea nitrogen 31, creatinine 1.56 mg/dL; eGFR 36. Repeat two to four weeks after today's losartan increase |
| Laboratory | Urine albumin-to-creatinine ratio | Repeat to confirm; three to six months after a treatment change; then about twice a year at G3b A2 | Due | Three months after treatment began |
| Medication safety | Medication review: NSAIDs, contrast, dose adjustment, sick-day rules | Every visit | Completed today | No NSAIDs; medicines checked for kidney dosing |
| Medication safety | Medicine safety: dizziness, genital infection, urine volume, sick-day rules | After starting an SGLT2 inhibitor | Completed today | No dizziness, genital infection or sick days |
| Laboratory | Hemoglobin | At least yearly at G3; recheck in three months when mildly low | Due | At three months |
| Laboratory | Calcium, phosphate, intact PTH and 25-hydroxyvitamin D | Baseline at G3; then every 6 to 12 months; vitamin D and PTH three months after starting replacement | Due | PTH and vitamin D at three months on vitamin D3 |
| Medication safety | Vaccines for kidney disease (influenza, pneumococcal, hepatitis B, COVID-19) | Review yearly; hepatitis B series if not immune | Completed today | COVID-19 vaccine today; influenza, PCV20, hepatitis B series, RSV and zoster dose 1 done; zoster dose 2 due in two to six months; hepatitis B antibody check due |
| Referral | Nephrology | When 5-year kidney failure risk is 3 to 5% or more, eGFR falls quickly, or the cause is unclear | Due | Review with Dr. Lindqvist-Moore at three months |
Goal progress:
Immunizations given today: COVID-19 vaccine, mRNA, this season [S]
Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update (2017); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Potassium and creatinine in two to four weeks. Review with the urine albumin, hemoglobin, PTH and vitamin D in three months, and nephrology review then. Call for dizziness, vomiting or diarrhea (hold losartan and dapagliflozin that day), or swelling of the lips or tongue (call 911). [S]